MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis
USA - NASDAQ:MESO - US5907174016 - ADR
15.53 USD
0 (0%)
MESO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. MESO has a bad profitability rating. Also its financial health evaluation is rather negative. MESO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MESO has reported negative net income.
In the past year MESO has reported a negative cash flow from operations.
MESO had negative earnings in each of the past 5 years.
MESO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -13.02%, MESO belongs to the best of the industry, outperforming 82.67% of the companies in the same industry.
MESO's Return On Equity of -17.10% is amongst the best of the industry. MESO outperforms 86.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| ROIC | N/A |
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MESO has a better Gross Margin (70.17%) than 81.17% of its industry peers.
In the last couple of years the Gross Margin of MESO has grown nicely.
MESO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
2. Health
2.1 Basic Checks
MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MESO has been increased compared to 1 year ago.
The number of shares outstanding for MESO has been increased compared to 5 years ago.
MESO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.66 indicates that MESO is not in any danger for bankruptcy at the moment.
MESO has a better Altman-Z score (4.66) than 74.39% of its industry peers.
MESO has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.12, MESO is not doing good in the industry: 64.60% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.66 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
A Current Ratio of 1.99 indicates that MESO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.99, MESO is doing worse than 75.33% of the companies in the same industry.
A Quick Ratio of 1.77 indicates that MESO should not have too much problems paying its short term obligations.
MESO's Quick ratio of 1.77 is on the low side compared to the rest of the industry. MESO is outperformed by 77.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
MESO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.05%.
MESO shows a strong growth in Revenue. In the last year, the Revenue has grown by 191.39%.
The Revenue for MESO have been decreasing by -11.76% on average. This is quite bad
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%
3.2 Future
The Earnings Per Share is expected to grow by 40.01% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 119.66% on average over the next years. This is a very strong growth
EPS Next Y54.99%
EPS Next 2Y45.83%
EPS Next 3Y42.96%
EPS Next 5Y40.01%
Revenue Next Year431.05%
Revenue Next 2Y234.53%
Revenue Next 3Y201.46%
Revenue Next 5Y119.66%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MESO's earnings are expected to grow with 42.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.83%
EPS Next 3Y42.96%
5. Dividend
5.1 Amount
MESO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MESO (11/12/2025, 2:41:22 PM)
15.53
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.47%
Inst Owner Change0.15%
Ins Owners17.98%
Ins Owner ChangeN/A
Market Cap1.99B
Revenue(TTM)17.20M
Net Income(TTM)-102.14M
Analysts78
Price Target15.66 (0.84%)
Short Float %2.93%
Short Ratio10.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.82%
PT rev (3m)30.96%
EPS NQ rev (1m)0.14%
EPS NQ rev (3m)N/A
EPS NY rev (1m)28.4%
EPS NY rev (3m)27.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)39.19%
Revenue NY rev (3m)37.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 115.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.33 | ||
| P/tB | 77.78 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.13
BVpS4.66
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.17% | ||
| FCFM | N/A |
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
F-Score6
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 3.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.99 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | 4.66 |
F-Score6
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.02%
Cap/Sales(5y)7.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.77%
EPS Next Y54.99%
EPS Next 2Y45.83%
EPS Next 3Y42.96%
EPS Next 5Y40.01%
Revenue 1Y (TTM)191.39%
Revenue growth 3Y18.97%
Revenue growth 5Y-11.76%
Sales Q2Q%458.55%
Revenue Next Year431.05%
Revenue Next 2Y234.53%
Revenue Next 3Y201.46%
Revenue Next 5Y119.66%
EBIT growth 1Y-23.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.98%
EBIT Next 3Y93.35%
EBIT Next 5YN/A
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.09%
OCF growth 3YN/A
OCF growth 5YN/A
MESOBLAST LTD- SPON ADR / MESO FAQ
What is the ChartMill fundamental rating of MESOBLAST LTD- SPON ADR (MESO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MESO.
What is the valuation status of MESOBLAST LTD- SPON ADR (MESO) stock?
ChartMill assigns a valuation rating of 1 / 10 to MESOBLAST LTD- SPON ADR (MESO). This can be considered as Overvalued.
Can you provide the profitability details for MESOBLAST LTD- SPON ADR?
MESOBLAST LTD- SPON ADR (MESO) has a profitability rating of 3 / 10.
Can you provide the financial health for MESO stock?
The financial health rating of MESOBLAST LTD- SPON ADR (MESO) is 3 / 10.